AndroGel 1.62%
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
May 12, 2020 → Jan 7, 2022
NCT ID
NCT04274894About AndroGel 1.62%
AndroGel 1.62% is a approved stage product being developed by AbbVie for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT04274894. Target conditions include Hypogonadism.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04274894 | Approved | Completed |
Competing Products
20 competing products in Hypogonadism